Amlodipine News and Research

RSS

HealthTrans Access sponsors 50 disadvantaged families to free healthcare support

HealthTrans Access, a comprehensive discount healthcare provider, has arranged for 50 disadvantaged families from the Greater Denver and Boulder areas to receive one year of membership in the HealthTrans Access discount healthcare program at no cost. In partnership with Denver Human Services and several of their community organizations, HealthTrans Access is providing families with its Premium discount program, which provides deep discounts for healthcare services for the entire family.

17 Nov 2009

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009.

3 Nov 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

Diuretic drug works best at reducing risk of heart failure in hypertension

New research supports the findings of a landmark drug comparison study published in 2002 in which a diuretic drug or "water pill" outperformed other medications for high blood pressure. A scientific team including investigators from The University of Texas Health Science Center at Houston reports the findings in the May 11 issue of the Archives of Internal Medicine.

13 May 2009

ACE inhibitor calcium channel blocker combo drug shown to reduces heart attacks

While doctors are urged to start with a diuretic-based strategy to control patients' high blood pressure, an international blood pressure study shows a different single-pill drug combination is more effective at preventing heart-related events such as heart attacks and strokes.

3 Dec 2008

Diuretic reduces risk for type of heart failure that affects women more often than

New research by The University of Texas School of Public Health shows that a medication for high blood pressure called a diuretic or water pill is particularly effective at reducing the risk for a type of heart failure that affects women more often than men.

11 Nov 2008

Ranbaxy and Pfizer settle on Lipitor patent litigation

Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine.

19 Jun 2008

Mylan confirms Azor patent challenge

Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.

4 Jun 2008

Two drug combo blood pressure therapy lowers cardiovascular risk

An international blood pressure study comparing two single-pill drug combinations has yielded results so significant that the study has been stopped early and the researchers say their findings might alter the way high blood pressure is treated worldwide.

1 Apr 2008

Evidence strongly supports diuretics as initial metabolic syndrome therapy, especially in black patients

New research shows that in people with high blood pressure as part of metabolic syndrome, a cluster of conditions that increases the risk for heart disease, diuretics offer greater protection against cardiovascular disease, including heart failure, and are at least as effective for lowering blood pressure as newer, more expensive medications.

28 Jan 2008

Gene variations associated with effectiveness of blood pressure medications

Patients with hypertension and certain gene variations experienced varying results with some blood pressure medications, suggesting matching a patient's genotype with certain hypertension medications could result in more favorable outcomes, according to a study in the January 23 issue of JAMA: The Journal of the American Medical Association.

23 Jan 2008

FDA to review potential anti-arrhythmic claims for Ranexa

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).

10 Dec 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Norvasc

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg (Amlodipine).

5 Dec 2007

Lupin receives approval for Amlodipine tablets

Lupin Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

18 Jul 2007

Ranbaxy receives approval to manufacture and market Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

11 Jul 2007

Roxane Laboratories announces launch of Amlodipine Besylate tablets

Roxane Laboratories, Inc. has announced the approval of its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5mg, 5mg, and 10mg by the U.S. Food and Drug Administration.

10 Jul 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007